- Live Vaccines
- Cell free PA Vaccines
Anthrax Vaccine Market size was valued at USD 10.67 billion in 2022 and it is estimated to reach at a USD 11.83 billion in 2029, growing at a significant CAGR of 7.5% from 2023-29. Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. The market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the market.
Global Anthrax Vaccine Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.5%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Anthrax Vaccine Market Dynamics
The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA-approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.
North-America Got Significant Share
Anthrax Vaccine Market Regional Analysis
Geographically, global anthrax vaccine market is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. The presence of various ongoing programs under the organizations such as BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors for the revenue generation in North America region. Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. The extensive vaccine manufacturing facilities across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The Anthrax Vaccine Market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Anthrax Vaccine Market Segmentation
By Type
By End User
- Hospitals
- Clinics,
- Vaccination Centers
- Others
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
The Anthrax Vaccine Market is growing at a CAGR of 7.5% over the Forecast Period
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
Emergent BioSolutions , Elusys Therapeutics, Panacea Biotec, Zoetis, Bayer, Colorado Serum Company, Inc, Biogénesis Bago, Emergent BioSolutions, Porton Biopharma Ltd, Merial, Merck, Altimmune, Inc. PharmAthene US Corp, Agrovet, CAVAC, Centro Diagnóstico Veterinario, Ceva Sante Animale
| 1.Executive Summary |
| 2.Global Anthrax Vaccine Market Introduction |
| 2.1.Global Anthrax Vaccine Market - Taxonomy |
| 2.2.Global Anthrax Vaccine Market - Definitions |
| 2.2.1.Basis Of Type |
| 2.2.2.End User |
| 2.2.3.Region |
| 3.Global Anthrax Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Anthrax Vaccine Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Anthrax Vaccine Market By Basis Of Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Live Vaccines |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Cell free PA Vaccines |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Anthrax Vaccine Market By End User , 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Hospitals |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Clinics |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Vaccination Centers |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Others |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7.Global Anthrax Vaccine Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Basis Of Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Live Vaccines |
| 8.1.2.Cell free PA Vaccines |
| 8.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospitals |
| 8.2.2.Clinics |
| 8.2.3.Vaccination Centers |
| 8.2.4.Others |
| 8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Live Vaccines |
| 9.1.2.Cell free PA Vaccines |
| 9.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospitals |
| 9.2.2.Clinics |
| 9.2.3.Vaccination Centers |
| 9.2.4.Others |
| 9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 9.3.7. |
| 10.Asia Pacific (APAC) Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Live Vaccines |
| 10.1.2.Cell free PA Vaccines |
| 10.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospitals |
| 10.2.2.Clinics |
| 10.2.3.Vaccination Centers |
| 10.2.4.Others |
| 10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Live Vaccines |
| 11.1.2.Cell free PA Vaccines |
| 11.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospitals |
| 11.2.2.Clinics |
| 11.2.3.Vaccination Centers |
| 11.2.4.Others |
| 11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Anthrax Vaccine Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Basis Of Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Live Vaccines |
| 12.1.2.Cell free PA Vaccines |
| 12.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospitals |
| 12.2.2.Clinics |
| 12.2.3.Vaccination Centers |
| 12.2.4.Others |
| 12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Emergent BioSolutions , |
| 13.2.2.Elusys Therapeutics , |
| 13.2.3.Porton Biopharma Limited , |
| 13.2.4.Panacea Biotec, |
| 13.2.5.Zoetis, |
| 13.2.6.Bayer, |
| 13.2.7.Emergent BioSolutions, |
| 13.2.8.Merial, Merck, |
| 13.2.9.Altimmune, Inc. |
| 13.2.10.PharmAthene US Corp, |
| 13.2.11.Agrovet, |
| 13.2.12.CAVAC, |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Emergent BioSolutions ,
- Elusys Therapeutics ,
- Porton Biopharma Limited ,
- Panacea Biotec,
- Zoetis,
- Bayer,
- Colorado Serum Company, Inc.,
- Biogénesis Bago,
- Emergent BioSolutions,
- Merial, Merck,
- Altimmune, Inc.
- PharmAthene US Corp,
- Agrovet,
- CAVAC,
- Centro Diagnóstico Veterinario,
- Ceva Sante Animale.